← Back to patent-cliff list
Methylphenidate (Inspirion)
Tier C — Watch / tradeMethylphenidate (Inspirion)
Inspirion Delivery Sciences
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ADRA2
Indications (approved)：脑癌, Fatigue, Attention deficit hyperactivity disorder
Regional status
US
No progress
2012-03-03
EU
Phase III
2025-09-02
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Methylphenidate (Inspirion)?
Approved indications include: 脑癌, Fatigue, Attention deficit hyperactivity disorder.
When does the Methylphenidate (Inspirion) patent expire?
No public expiry year is available for Methylphenidate (Inspirion) yet; this page updates once verified.
How do I get a quote for Methylphenidate (Inspirion) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30